Country Trust Bank’s CRISPR Therapeutics CRSP Stock Holding History

Country Trust Bank’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$27.3K	Hold	500	–	–	﹤0.01%	245
2026 Q1	$23.8K	Sell	500 -100	-17%	-$5.27K	﹤0.01%	237
2025 Q4	$31.5K	Hold	600	–	–	﹤0.01%	220
2025 Q3	$38.9K	Hold	600	–	–	﹤0.01%	221
2025 Q2	$29.2K	Buy	600 +100	+20%	+$3.87K	﹤0.01%	230
2025 Q1	$17K	Hold	500	–	–	﹤0.01%	222
2024 Q4	$19.7K	Hold	500	–	–	﹤0.01%	223
2024 Q3	$23.5K	Hold	500	–	–	﹤0.01%	212
2024 Q2	$27K	Hold	500	–	–	﹤0.01%	196
2024 Q1	$34.1K	Hold	500	–	–	﹤0.01%	186
2023 Q4	$31.3K	Hold	500	–	–	﹤0.01%	185
2023 Q3	$22.7K	Hold	500	–	–	﹤0.01%	205
2023 Q2	$28.1K	Hold	500	–	–	﹤0.01%	196
2023 Q1	$22.6K	Hold	500	–	–	﹤0.01%	199
2022 Q4	$20.3K	Hold	500	–	–	﹤0.01%	225
2022 Q3	$33K	Buy	+500	New	+$36.2K	﹤0.01%	211

Other funds holding CRSP

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

PAG

Private Advisor Group Morristown, New Jersey $21.8B AUM 28.57% 1-Year Est. Return

EWA

EverSource Wealth Advisors Birmingham, Alabama $2.97B AUM 28.74% 1-Year Est. Return

CAM

Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

Slow Capital Greenbrae, California $857M AUM 38.3% 1-Year Est. Return

CIA

Concurrent Investment Advisors Tampa, Florida $11.8B AUM 31.86% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return

BEI

Benjamin Edwards Inc Clayton, Missouri $11B AUM 18.22% 1-Year Est. Return

Cambridge Investment Research Advisors Fairfield, Iowa $44.6B AUM 28.94% 1-Year Est. Return

CIC

Canal Insurance Company Greenville, South Carolina $456M AUM 40.11% 1-Year Est. Return

Country Trust Bank's CRSP Position: Q2 2026 in Review

Country Trust Bank held its CRISPR Therapeutics (CRSP) position steady in Q2 2026 at 500 shares worth $27.3K. The position accounts for ﹤0.01% of the portfolio, ranked #245.

Country Trust Bank first reported a position in CRSP in Q3 2022 and has held it in 16 quarters since. The position peaked at $38.9K in Q3 2025. 151 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

Country Trust Bank held 500 shares of CRISPR Therapeutics worth $27.3K as of Q2 2026.
Country Trust Bank left its CRISPR Therapeutics share count unchanged in Q2 2026.
CRISPR Therapeutics made up ﹤0.01% of Country Trust Bank's portfolio in Q2 2026, its #245 holding.
Country Trust Bank first reported a position in CRISPR Therapeutics in Q3 2022 and has held it in 16 quarters since.
Country Trust Bank's CRISPR Therapeutics position peaked at $38.9K in Q3 2025.
151 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Country Trust Bank's 13F filing for Q2 2026, filed 15 Jul 2026.